CHELSEA FUJITA-HAFFNER: Open Payments
NPI 1841832847 · GLENDORA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,717 in 121 payments from 15 companies in 2025. Trend: 2023 $2,117 · 2024 $1,699 · 2025 $3,717
Food & beverage: $3,019Travel & lodging: $698
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 46 | $1,322 |
| Boston Scientific Corporation | 5 | $1,007 |
| Janssen Biotech, Inc. | 12 | $352 |
| Ardelyx, Inc. | 12 | $263 |
| ABBVIE INC. | 23 | $262 |
| GENZYME CORPORATION | 3 | $88 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $83 |
| Phathom Pharmaceuticals, Inc. | 4 | $74 |
| Novo Nordisk Inc | 3 | $71 |
| Regeneron Healthcare Solutions, Inc. | 2 | $60 |
Products named: REZDIFFRA, General - Therapies, TREMFYA, IBSRELA, DUPIXENT, CREON, XIFAXAN, VOQUEZNA.
Industry payments across CA — which companies pay providers there.
